Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

National Study of Prevalence of Creatinine Phosphokinase (CPK) Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases (TKI)

NCT01248429 is registered in ClinicalTrials.gov with Centre Oscar Lambret as lead sponsor.

NCT NCT01248429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01248429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
National Study of Prevalence of Creatinine Phosphokinase (CPK) Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases (TKI)
Lead sponsor
Centre Oscar Lambret
Phase
Observational
Overall status
Completed
Start date
November 30, 2010
Completion date
January 15, 2013
Enrollment
154 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, solid tumor